PM360

DECEMBER 20, 2024

I think that it’s very important for biosimilars that health plans allow physicians to prescribe the biosimilar, or at least provide an option of a biosimilar as that first-line treatment, Chambers said. Exhibit 1, below, shows coverage status of originator and biosimilar products for US commercial payers from 2017 to 2022.

Physicians 52

Physicians Marketing Competition Management 52

Medgadget

MARCH 2, 2023

To make implantation of the Alpha DaRT sources easy and precise, the company developed dedicated applicators andadapted existing biopsy devices, that physicians are already acquainted with, to deliver the radioactive sources. Results from initial clinical trials were quite impressive. More info can be found at the Biomed Israel website.

Manufacturing 82

Manufacturing Leads Patients Medicine 82

European Pharmaceutical Review

MAY 23, 2024

In this Q&A, Dr Imran Khan, PhD, Vice President Medical Affairs, Hematology at Johnson & Johnson Innovative Medicine, highlights the current landscape of CAR T therapies such as CARVYKTI and touches on the future direction of the sector. Most recently, Imran has served as Medical Science Liaison (MSL) Head, Oncology U.S.

Food and Drug Administration 110

Food and Drug Administration Food Medical Medicine 110